Related Experiment Video
Updated: Sep 15, 2025
Coculture Assays to Study Macrophage and Microglia Stimulation of Glioblastoma Invasion
Published on: October 20, 2016
ApoE Inhibits the Progression of Glioma by Activating Immune Function
Xiao-Fei Liu1,2, Yu-Jie Chang1, Min Long1
1Hengyang Medical School, University of South China, Hengyang, Hunan, China.
Abstract:
Glioma, marked by a low mutational burden, low immunogenicity, high heterogeneity, and the challenges posed by the blood-brain barrier, continues to be a major hurdle in neuro-oncology. Current research underscores the necessity for more effective medications and treatment strategies. In this study, we explored the role of Apolipoprotein E (ApoE) in glioma using both bioinformatics and experimental methods. The construction of our bioinformatics risk model identified ApoE as a protective factor linked to longer survival in glioma patients. Subsequently, we created an in situ tumorigenic mouse model and a subcutaneous tumorigenic mouse model with ApoE gene knockout to evaluate the functional impacts of ApoE deficiency in glioma. Our results demonstrated that ApoE deficiency accelerates the growth of glioma and encourages the invasive behaviour of tumour cells into normal brain tissue. Additionally, we detected a reduction in the immune surveillance of glioma in the context of ApoE deficiency. Furthermore, flow cytometry analysis indicated that the lack of ApoE led to a decrease in positive immune cells and an increase in immunosuppressive cells within the tumour microenvironment. Our findings suggest that ApoE plays a crucial role in modulating glioma progression and immune surveillance, highlighting its potential as a therapeutic target.
Insights
Apolipoprotein E (ApoE) is protective in glioma, as its deficiency accelerates tumor growth and invasion. ApoE loss also impairs anti-tumor immunity, suggesting ApoE as a potential therapeutic target for brain tumors.
Area of Science:
- Neuro-oncology
- Cancer immunology
- Molecular biology
Background:
- Glioma presents significant challenges due to low mutational burden, immunogenicity, heterogeneity, and the blood-brain barrier.
- Effective therapeutic strategies for glioma remain a critical unmet need in neuro-oncology.
- The role of Apolipoprotein E (ApoE) in glioma pathogenesis is not fully understood.
Purpose of the Study:
- To investigate the functional role of Apolipoprotein E (ApoE) in glioma progression and immune surveillance.
- To determine if ApoE deficiency impacts glioma growth, invasion, and the tumor microenvironment.
Main Methods:
- Bioinformatics analysis to construct a risk model and identify ApoE as a prognostic factor.
- Development of in situ and subcutaneous glioma mouse models with ApoE gene knockout.
- Flow cytometry to analyze immune cell populations within the tumor microenvironment.
Main Results:
- Bioinformatics model identified ApoE as a protective factor associated with improved glioma patient survival.
- ApoE deficiency accelerated glioma tumor growth and promoted invasive behavior into normal brain tissue.
- ApoE deficiency led to reduced anti-tumor immune surveillance, characterized by fewer immune-activating cells and more immunosuppressive cells.
Conclusions:
- Apolipoprotein E plays a significant role in regulating glioma progression and immune evasion.
- Targeting ApoE may represent a novel therapeutic strategy for improving glioma treatment outcomes.
- Further research into ApoE's mechanisms in glioma is warranted to develop targeted therapies.
Related Concept Videos
01:27Tumor Immunotherapy
01:17The Extrinsic Apoptotic Pathway